

Clinical study on collagen gel droplet-embedded culture drug sensitivity test for multidrug combination chemotherapy and super selective intra-arterial infusion chemoradiotherapy in oral squamous cell carcinoma

KANAME SAKUMA¹, RYUKI TAMURA², SHINTARO HANYU², HARUKA TAKAHASHI²,
HIDEAKI SATO¹, TAKAHIRO ONEYAMA¹, AKIRA YAMAGUCHI¹ and AKIRA TANAKA²

¹Department of Oral and Maxillofacial Surgery, Niigata Hospital, The Nippon Dental University, Niigata, Niigata 951-8580; ²Department of Oral and Maxillofacial Surgery, The Nippon Dental University School of Life Dentistry at Niigata, Niigata, Niigata 951-8580, Japan

Received July 13, 2017; Accepted October 17, 2017

DOI: 10.3892/mco.2017.1459

Abstract. Using trace three-dimensional culture, the collagen gel droplet-embedded culture drug sensitivity test (CD-DST) can be tested even in cases with a small number of cells, including oral squamous cell carcinoma (OSCC), and evaluation of the antitumor effect with a drug concentration close to the *in vivo* level is possible. The present report aimed to evaluate the utility of the CD-DST in the assessment of the *in vitro* efficacy of single-agent and multidrug combination chemotherapy for OSCC in comparison with the clinical response rates and to examine the possible clinical application of CD-DST for such cases. A total of 33 OSCC patients from whom 33 samples were obtained from January 2010 to September 2015 were included. CD-DST was performed, individually and in combination, on the three drugs [i.e., cisplatin (CDDP), 5-fluorouracil (5-FU), and docetaxel (DOC)] and on super selective intra-arterial infusion chemoradiotherapy (IACRT). The overall evaluable rate of the CD-DST in OSCC was 81.8% (27 of 33 cases) and the sensitivity to each anticancer drug was evaluated. The *in vitro* efficacy rates of IACRT, cisplatin + 5-fluorouracil, and docetaxel + cisplatin + 5-fluorouracil (TPF) confirmed the estimated clinical response rates. In 14 of 33 patients, the results of CD-DST were compared with clinical efficacy, which was judged based on measurable lesions on imaging. For TPF therapy, the sensitivity test of the IACRT had a positive

predictive value of 90.9% (10 of 11 cases) and a negative predictive value of 100% (3 of 3 cases); the accuracy of the susceptibility test for the anticancer agents was 92.8% (13 of 14 cases). The CD-DST may be useful in selecting multidrug combination chemotherapy and IACRT for OSCC, however, accumulation of further clinical data is required in the future.

Introduction

The treatment of advanced or unresectable oral squamous cell carcinoma (OSCC) is multidisciplinary and entails the use of both multidrug combination chemotherapy and radiotherapy (1-3). The usefulness of super selective intraarterial infusion chemoradiotherapy (IACRT) to deliver high concentrations of anticancer drugs to tumors has been reported (4). The selection of such anticancer drugs for IACRT had been based on statistical information and clinical reports on a number of cases (1-3); however, the expected therapeutic effects of these anticancer drugs have not been consistent and adverse events were common. Therefore, drug sensitivity testing prior to administration of an anticancer agent is ideal to avoid the serious side effects of less effective anticancer drugs. Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) uses an image colorimetric method to assess the combination of an anticancer drug and microcollagen gel embedded in a three-dimensional serum-free culture medium (3 to 10x10³ cells/30 µg/drop) (5,6). It is a susceptibility test that is currently widely applied in various clinical fields, including gastrointestinal cancer (7-9). However, reports on the use of CD-DST in OSCC were few and none have evaluated multidrug combination chemotherapy or IACRT.

CD-DST is usually carried out on surgical and biopsy specimens. In this study, we aimed to evaluate the utility of the CD-DST in the assessment of the *in vitro* efficacy of single-agent and multidrug combination chemotherapy for OSCC in comparison with the clinical response rates and to examine the possible clinical application of the CD-DST for such cases.

Correspondence to: Dr Kaname Sakuma, Department of Oral and Maxillofacial Surgery, Niigata Hospital, The Nippon Dental University, 1-8 Hamaura-cho, Chuo-ku, Niigata, Niigata 951-8580, Japan
E-mail: sakuma.k@ngt.ndu.ac.jp

Key words: anticancer drug sensitivity test, oral squamous cell carcinoma, collagen gel droplet-embedded culture drug sensitivity test, multidrug combination chemotherapy, super selective intraarterial chemoradiotherapy

Patients and methods

The subjects comprised 33 OSCC patients who gave consent to participate in the study from January 2010 to September 2015 at Nippon Dental University Niigata Hospital Oral Maxillofacial Surgery (Table I). The Ethics Committee of The Nippon Dental University School of Life Dentistry at Niigata approved the present study (approval no. ECNG-H-119).

CD-DST was performed on 31 primary lesions and 2 metastatic lymph nodes; 5-7-mm² tissues (about 0.25-0.5 mg) were collected mainly from the area surrounding the hardened part of the tumor. CD-DST was carried out according to the method invented and reported by Kobayashi *et al* (5,6), who used a human tumor cell primary culture system kit (Primaster®; Kurabo Industries Ltd., Osaka, Japan). Briefly, each sample was washed five times with 50 ml saline containing 1.0 mg/ml penicillin, 0.5 mg/ml kanamycin, and 2.5 µg/ml amphotericin B; this was followed by treatment with Dispersion Enzyme Cocktail EZ (Primaster® reagent). The obtained cell suspension samples were inoculated into collagen gel-coated flasks (CG flasks, a Primaster® device) and were inoculated overnight in a pre-culture medium PCM-1 (Primaster® content) at 37°C in 5% CO₂. Next, the collagen gel was digested with 0.05% EZ and viable cancer cells were obtained. Type I collagen, F-12 medium that was 10 times concentrated, and reconstitution buffer were mixed together in ice water at a ratio of 8:1:1 (Primaster® content). The prepared cancer cell suspension was added to the collagen solution at a final density of 1x10⁵ cells/ml. Three drops of the collagen-cell mixture (30 µl/drop) were placed in a 6-well plate on ice and was allowed to solidify at 37°C in a CO₂ incubator; the final concentration was about 3x10³ cells per collagen gel droplet. One hour later, a DF medium containing 10% fetal bovine serum was overlaid in each well; the plates were placed in a CO₂ incubator overnight at 37°C. The anticancer drugs were added with the following final concentrations and incubated for 24 h: 0.5 µg/ml cisplatin (CDDP) (10), 0.7 µg/ml fluorouracil (5-FU) (10), and 0.1 µg/ml docetaxel (DOC) (11). For cases that needed multidrug combination chemotherapy, the respective concentrations were placed together in the same well. The duration of CDDP contact, even at a concentration 2.5 µg/ml (CDDP extreme contact) for IACRT, was the same at 24 h. The concentration of each anticancer drug in the culture medium was determined so as to exhibit area under the curve values that were similar to those in serum during the first 24 h of intravenous administration of the corresponding drug at the standard clinical dosage. After removal of the medium containing the anticancer drugs, each well was rinsed twice with 3 ml of Hanks' balanced salt solution, overlaid with 4 ml of PCM-2 medium (Primaster® serum-free medium), and incubated for seven more days. At the end of the incubation, a neutral red solution was added to each well to make a final concentration of 50 µg/ml; colonies in the collagen gel droplets were stained for two h. Each collagen droplet was fixed with 10% neutral buffered formalin, washed in water, air dried, and quantified by optical density image analysis using the Primage System (Solution Systems, Tokyo, Japan).

In vitro sensitivity was expressed as the T/C ratio of the optical density, where T represented the treated samples and C represented the controls; a T/C ratio of <50% was regarded as chemosensitive *in vitro*. A tumor cell colony volume ratio

Table I. Characteristics of patients (N=33).

	Number of patients (%)
Sex	
Male	22 (66.6)
Female	11 (33.3)
Age, years	
Mean	74 (37–95)
Histology (Squamous cell carcinoma)	
Differentiation	
Well-differentiated	24 (72.7)
Moderately-differentiated	6 (18.1)
Poorly-differentiated	3 (9.0)
Stage	
I	2 (6.0)
II	12 (36.3)
III	6 (18.1)
IV	13 (39.3)
Primary site	
Tongue	13 (39.3)
Buccal mucosa	7 (21.2)
Oral floor	4 (12.1)
Gingiva	8 (24.2)
Hard palate	1 (3.0)
Resection mode	
Biopsy	27 (81.8)
Surgery	4 (12.1)
Sample site	
Neck metastasis	2 (6.0)
Primary	31 (93.9)
Others (Neck metastasis)	2 (6.0)
CD-DST	
Success	27 (81.8)
Failure	6 (18.2)

CD-DST, collagen gel droplet-embedded culture drug sensitivity test.




Figure 1. Overview of the collagen gel droplet-embedded culture drug sensitivity test method.

Table II. Evaluable rate of the clinical specimens of OSCC on CD-DST.

	Primary lesion	Metastatic lymph node	Total
Number of samples	31	2	33
Evaluable cases	26	1	27
Evaluable rate (%)	83.8 (26/31) ^a	50.0 (1/2)	81.8 (27/33)

^aNumber of success cases/total number of assays.

Table III. *In vitro* sensitivity and clinical efficacy rates of the individual drugs for OSCC

	CDDP	5-FU	DOC	TPF	PF	IACRT
CD-DST <i>in vitro</i>	23.8	30.0	37.5	80.7	22.2	87.5
Efficacy rate (%)	(5/21) ^a	(3/10)	(3/8)	(21/26)	(4/18)	(14/16)
Clinical efficacy rate (%)	26.3 (13)	13.0 (14)	10.0 (15)	80.6 (16)	20.0-30.0 (17,18)	85.0-91.2 (19,20) ^b

In vitro drug sensitivity was defined as positive when the T/C ratio was $\leq 50\%$. CD-DST, collagen gel droplet-embedded culture drug sensitivity test; CDDP, cisplatin; 5-FU, 5-fluorouracil; DOC, docetaxel; TPF, DOC+CDDP+5-FU; PF, CDDP+5-FU; IACRT, super selective intraarterial infusion chemoradiotherapy. ^aNumber of effective cases/total number of assays. ^bEvaluated with complete response only.

(tumor growth rate) at 0 time was calculated from the control group; a value of less than 0.8 was regarded as unsuccessful culture (low growth rate), regardless of the tumor cell colony volume of the control group.

Retrospective comparison between clinical response, as measured by tumor shrinkage and the results of drug sensitivity on CD-DST was conducted on 14 cases (42.4%) that had measurable lesions on imaging. We studied five cases of TPF therapy and nine cases of IACRT; TPF therapy was intravenously administered with DOC: 50 mg/m², CDDP: 50 mg/m², 5-FU: 2,500 mg/m². The latter was administered weekly using CDDP at a cumulative dose of 80-460 mg/body (median, 350 mg/body) and radiation therapy was given at 2 Gy/day at a cumulative dose of 56-72 Gy (median, 66 Gy). Response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (12). Partial response (PR) and complete response (CR) were judged to be sensitive.

Fisher's exact test was used to determine differences between groups. A value of $P < 0.05$ was considered statistically significant (SPSS, Inc., Chicago, IL, USA).

Results

Evaluable rate of clinical specimens. CD-DST in OSCC had an overall evaluable rate of 81.8% (27 of 33 cases) and could be applied to each of the anticancer agent in this study. The evaluable rate was 83.8% (26 of 31 cases) for primary lesions and 50% (1 of 2 cases) for metastatic lymph nodes (Table II). Causes of unsuccessful CD-DST were insufficient tumor cells (growth rate less than 0.8) in three cases and bacterial contamination in three cases. The mean tumor growth rate was 10.1 ± 4.92 .

Comparison between *in vitro* effective rate and clinical response rate of various anticancer drugs. Results of the

comparison between the *in vitro* effective rates and clinical response rates of representative anticancer drugs for clinical treatment of OSCC (13-20) are shown in Table III. 5-FU and DOC had slightly higher clinical response rates than *in vitro* effective rates, but CDDP had comparable clinical response and *in vitro* effective rates. The *in vitro* effective rates and clinical response rates were comparable in docetaxel + cisplatin + 5-fluorouracil (TPF) and cisplatin + 5-fluorouracil (PF) therapies, as well as in CDDP at high concentrations mimicking IACRT. In addition, no significant difference was observed among the susceptibilities of various anticancer agents, regardless of stage and histologic differentiation ($P > 0.05$).

Comparison between clinical response and anticancer drug sensitivity test. The clinical response of 14 patients with measurable lesions by imaging diagnosis is shown in Table IV. Among patients who received TPF therapy, three had PR and two had stable disease (SD). For those who received IACRT, eight cases had CR and one case had progressive disease (PD). There were three cases of TPF therapy and seven cases of IACRT that were determined by the CD-DST to be highly sensitive. The corresponding drug sensitivity test results of the 14 are shown in Table V. Among the cases that received TPF therapy and IACRT, all three cases with PR and seven of eight cases with CR were highly sensitive; all cases with SD and PD had low sensitivity and agreed with the CD-DST. In the 88.8% (8 of 9 cases) who received IACRT, the results of the CD-DST performed at a high CDDP contact concentration revealed were correlated with the clinical results. In addition, in the 100% (5 of 5 cases) who received TPF, the results of the CD-DST performed at a TPF contact revealed were correlated with the clinical results. TPF therapy and IACRT had a positive predictive value of 90.9% (10 of 11 cases) and a negative

Table IV. Association between *in vitro* sensitivity rate and chemotherapeutic effect.

	Evaluated lesion	Treatment regimen	Clinical effect	Sensitivity test	T/C value (%)	Growth rate	CD-DST/clinical effect
1	Gingiva	TPF	PR	TPF	22.8	5.8	S/S
2	Tongue	TPF	PR	TPF	27.7	15.03	S/S
3	Buccal mucosa	TPF	SD	TPF	54.2	7.96	R/R
4	Hard palate	TPF	SD	TPF	71.6	2.59	R/R
5	Tongue (metastatic lymph node)	TPF	PR	TPF	32.2	1.55	S/S
6	Tongue	IACRT	CR	CDDP (extreme)	19.4	11.22	S/S
7	Gingiva	IACRT	CR	CDDP (extreme)	31.2	2.89	S/S
8	Tongue	IACRT	CR	CDDP (extreme)	42.3	17.65	S/S
9	Gingiva	IACRT	CR	CDDP (extreme)	42.6	3.88	S/S
10	Gingiva	IACRT	PD	CDDP (extreme)	62.3	15.4	R/R
11	Tongue	IACRT	CR	CDDP (extreme)	11.6	9.13	S/S
12	Buccal mucosa	IACRT	CR	CDDP (extreme)	22.7	2.86	S/S
13	Tongue	IACRT	CR	CDDP (extreme)	34.0	1.39	S/S
14	Gingiva	IACRT	CR	CDDP (extreme)	118.0	0.87	R/S

In vitro drug sensitivity was defined as sensitive when the T/C rate was $\leq 50\%$. CD-DST, collagen gel droplet-embedded culture drug sensitivity test; T/C, total colony of the treated cells/total colony of the untreated cells; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; CDDP, cisplatin; 5-FU, 5-fluorouracil; DOC, docetaxel; TPF, DOC+CDDP+5-FU; IACRT, super selective intraarterial infusion chemoradiotherapy; S, sensitive; R, resistant.

Table V. Summary of the association between *in vitro* sensitivity data and chemotherapeutic effect.

	Chemotherapeutic effect			
	CR	PR	SD	PD
<i>In vitro</i> chemosensitivity data				
High sensitivity	7	3	0	0
Low sensitivity (resistant)	1	0	2	1

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.

predictive value of 100% (3 of 3 cases). The diagnostic accuracy was 92.8% (13 of 14 cases).

Discussion

The standard chemotherapy in the head and neck region that were reported to exert beneficial effects comprises PF therapy, which is a combination of CDDP and a 5-FU-type pyrimidine antimetabolite (17,18), and TPF therapy, which is a combination of CDDP, 5-FU, and a taxane type of anticancer drug (1-3). However, TPF therapy had been reported to have high rates of adverse reactions, including grade 3 or higher neutropenia at 76.9 to 83.0%, febrile neutropenia at 5.2 to 12.0%, and severe hematologic toxicity, in addition to mucositis, nausea, and vomiting (21,22). From this point of view, the clinical application of *in vitro* chemosensitivity test is a promising strategy.

There have been previously published *in vitro* methods of anticancer drug sensitivity test, such as the human tumor clonogenic assay and the succinate dehydrogenase inhibition test; however, the success rate of these two-dimensional primary culture methods have been limited by drug contact concentration (23,24). On the other hand, the CD-DST that we performed in this study had a potential for a high success rate on initial culture, needed a small number of cells, and used serum-free culture medium and image colorimetry to eliminate the influence of fibroblasts. The CD-DST has the advantage of using an anticancer drug contact concentration that is comparable to the clinical therapeutic dose (5,6,10,25). In fact, the primary measurement success rate of the CD-DST was reported to be 87.5% in colorectal cancer, 79.2% in lung cancer, and 84.3% in breast cancer (11,26,27). For OSCC, the primary culture rate was 83.8% (26 of 31 cases) for primary tumors, 50% (1 of 2 cases) for metastatic lymph nodes, and 81.8% (27 of 33 cases) overall.

Notably, CD-DST was clinically applicable even with the use of small tissue specimens of OSCC. For cases that could not be evaluated by the CD-DST, the lack of cells may have been due to biopsy technique. Yamamoto *et al* (28) reported that in breast cancer, sampling should be performed mainly from the central part of the tumor. In the non-evaluable cases in this study, collection of OSCC samples may have been from the superficial necrotic portions of the tumor. Therefore, it is important to collect tumor specimens from the hardened portions during biopsy.

Kobayashi *et al* (5,6) reported a statistically significant correlation between *in vitro* efficacy on CD-DST and clinical response in breast cancer, gastric cancer, colorectal cancer, and lung cancer. In this study on OSCC, the 80.7% *in vitro*

efficacy rate of TPF therapy was comparable to the previously reported 80.6% clinical response rate to preoperative TPF chemotherapy (16). Furthermore, the 22.2% *in vitro* efficacy rate of PF therapy in this study was comparable to the reported clinical response rate of 20 to 30% (17,18). For multidrug combination therapy, it was suggested that the *in vitro* effective rate on CD-DST reproduced the clinical response rate. Drug sensitivity test of IACRT has not been reported; as a substitute and to reproduce the clinical response rate of IACRT in combination with radiation therapy, a high concentration contact of CDDP was used. As a result, the 87.5% *in vitro* efficacy rate of IACRT was comparable to the previously reported 85 to 91.2% (19,20). In the 88.8% (8 of 9 cases) who received IACRT, the results of the CD-DST performed at a high CDDP contact concentration revealed were correlated with the clinical results. Our results suggested that a high contact concentration of CDDP can be applied to represent CD-DST of IACRT in OSCC.

In one patient (case 14), the result of the susceptibility test and clinical effect were different. Nakagawa *et al* (29) reported that if the growth rate was low, the sensitivity may be underestimated because the denominator of the T/C value decreases. Case 14 had a low growth rate of 0.87, suggesting the possibility of underestimating as reported. Therefore, further improvement of culture conditions is important to obtain accurate drug sensitivity test results.

A comparison of the clinical effect judgment of preoperative TPF therapy and IACRT which was treated with OSCC and the sensitivity test result of CD-DST revealed that the clinical correlation rate was 92.8% (13 of 14 cases) in combine with TPF therapy and IACRT, which reflected the clinical effect adequately. The clinical correlation rate of the CD-DST in OSCC was comparable to the previously reported clinical correlation rate of 91% for breast cancer, gastric cancer, and rectal cancer (6). From these results, CD-DST may predict the response of OSCC to multidrug combination therapy and the therapeutic effect IACRT.

In the future, cancer chemotherapy based on drug susceptibility test, including that for OSCC, could enable appropriate selection of patients, as well as treatment regimens that emphasize function preservation; improve quality of life; and provide treatment options for unresectable and refractory cases. However, Suzuki *et al* (30) reported differences in anticancer drug sensitivity testing between primary and metastatic OSCC tumors and suggested repeat chemotherapy drug sensitivity testing for metastatic/recurrent cases. The timing and performance of drug susceptibility test for recurrent/metastatic OSCC tumors need investigation in the future. In addition, accumulation and analysis of additional cases are necessary to verify our results on CD-DST in OSCC patients. Further study on the correlation between clinical effect and survival rate should be carried out to determine the range of clinical application of the CD-DST in OSCC.

In conclusion, CD-DST data of TPF and IACRT obtained by biopsy or surgical-fresh specimens of OSCC correlated to the disease control effects of chemotherapy for it. To select the chemotherapy regimen and to expect a better response from each patient with OSCC, the clinical application of this *in vitro* sensitivity test should be prospectively driven under clinical study using more OSCC patients.

References

1. Umeda M, Komatsubara H, Ojima Y, Minamikawa T, Shigeta T, Shibuya Y, Yokoo S and Komori T: Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU). *Kobe J Med Sci* 50: 189-196, 2004.
2. Katori H, Tsukuda M, Mochimatu I, Ishitoya J, Kawai S, Mikami Y, Matsuda H, Tanigaki Y, Horiuchi C, Ikeda Y, *et al*: Phase I trial of concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). *Br J Cancer* 90: 348-352, 2004.
3. Ahn JS, Cho SH, Kim OK, Lee JK, Yang DH, Kim YK, Lee JJ, Lim SC, Kim HJ, Chung WK and Chung IJ: The efficacy of an induction chemotherapy combination with docetaxel, cisplatin and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer. *Cancer Res Treat* 39: 93-98, 2007.
4. Fuwa N, Ito Y, Matsumoto A, Kamata M, Kodaira T, Furutani K, Sasaoka M, Kimura Y and Morita K: A combination therapy of continuous superselective intraarterial carboplatin infusion and radiation therapy for locally advanced head and neck carcinoma. Phase I study. *Cancer* 89: 2099-2105, 2000.
5. Kobayashi H, Tanisaka K, Kondo N, Mito Y, Koezuka M, Yokoyashi H, Higashiyama M, Kodama K, Doi O, Yamada M, *et al*: Development of new *in vitro* chemosensitivity test using collagen gel droplet embedded culture and its clinical usefulness. *Gan To Kagaku Ryoho* 22: 1933-1939, 1995 (In Japanese).
6. Kobayashi H, Tanisaka K, Doi O, Kodama K, Higashiyama M, Nakagawa H, Miyake M, Taki T, Hara S, Yasutomi M, *et al*: An *in vitro* chemosensitivity test for solid human tumors using collagen gel droplet embedded cultures. *Int J Oncol* 11: 449-455, 1997.
7. Naitoh H, Yamamoto H, Murata S, Kobayashi H, Inoue K and Tani T: Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer. *Gastric Cancer* 17: 630-637, 2014.
8. Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Inou T, Washio M, Sakuyama N, Sato T, Kishine K, *et al*: Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test. *Oncol Lett* 4: 621-624, 2012.
9. Mekata E, Sonoda H, Shimizu T, Tatsuta T, Yamaguchi T, Endo Y and Tani T: Clinical predictive value of *in vitro* anti-cancer drug sensitivity test for the therapeutic effect of adjuvant chemotherapy in patients with stage II-III colorectal cancer. *Mol Clin Oncol* 1: 763-767, 2013.
10. Sakuma K, Tanaka A and Mataga I: Collagen gel droplet-embedded culture drug sensitivity testing in squamous cell carcinoma cell lines derived from human oral cancers: Optimal contact concentrations of cisplatin and fluorouracil. *Oncol Lett* 12: 4643-4650, 2016.
11. Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H and Noguchi S: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. *Int J Cancer* 98: 450-455, 2002.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, *et al*: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 45: 228-247, 2009.
13. Inuyama Y and Takeda C: A cooperative phase II study of cisplatin in patients with head and neck cancer. *Gan To Kagaku Ryoho* 13: 232-238, 1986 (In Japanese).
14. Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L, *et al*: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. *J Clin Oncol* 10: 257-263, 1992.
15. Inuyama Y, Kataura A, Togawa K, Saijo S, Satake B, Takeoda S, Konno A, Ebihara S, Sasaki Y, Kida A, *et al*: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer. *Gan To Kagaku Ryoho* 26: 107-116, 1999 (In Japanese).
16. Zhong LP, Zhang CP, Ren GX, Guo W, William WN Jr, Sun J, Zhu HG, Tu WY, Li J, Cai Y, *et al*: Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. *J Clin Oncol* 31: 744-751, 2013.

17. Vermorken JB, Mesia R, Rivera F, Remenar E, Kaweckki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, *et al*: Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med* 359: 1116-1127, 2008.
18. Kiyota N, Tahara M, Kadowaki S, Fuse N, Doi T, Minami H and Ohtsu A: Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Efficacy and safety of a lower dose of PF (80/800) at a single institution in Japan. *Jpn J Clin Oncol* 39: 225-230, 2009.
19. Robbins KT, Kumar P, Harris J, McCulloch T, Cmelak A, Sofferman R, Levine P, Weisman R, Wilson W, Weymuller E and Fu K: Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: Results of Radiation Therapy Oncology Group Trial 9615. *J Clin Oncol* 23: 1447-1454, 2005.
20. Robbins KT, Kumar P, Regine WF, Wong FS, Weir AB III, Flick P, Kun LE, Palmer R, Murry T, Fontanesi J, *et al*: Efficacy of targeted supradose cisplatin and concomitant radiation therapy for advanced head and neck cancer: The memphis experience. *Int J Radiat Oncol Biol Phys* 38: 263-271, 1997.
21. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, *et al*: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. *N Engl J Med* 357: 1695-1704, 2007.
22. Posner MR, Herschock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, *et al*: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. *N Engl J Med* 357: 1705-1715, 2007.
23. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS and Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. *N Engl J Med* 298: 1321-1327, 1978.
24. Kondo T, Imamura T and Ichibashi H: In vitro test for sensitivity of tumor to carcinostatic agents. *Gan* 57: 113-121, 1966.
25. Inaba M, Tashiro T, Sato S, Ohnishi Y, Tanisaka K, Kobayashi H and Koezuka M: In vitro-in vivo correlation in anticancer drug sensitivity test AUC-based concentrations and collagen gel droplet embedded culture. *Oncology* 53: 250-257, 1996.
26. Araki Y, Isomoto H, Matsumoto A, Kaibara A, Yasunaga M, Hayashi K, Yatsugi H and Yamauchi K: An in vitro chemosensitivity test for colorectal cancer using collagen-gel droplet embedded cultures. *Kurume Med J* 46: 163-166, 1999.
27. Kawamura M, Inoue Y, Oyama T and Kobayashi K: Chemosensitivity test for unresectable non-small cell lung cancer. *Nihon Geka Gakkai Zasshi* 103: 229-232, 2002 (In Japanese).
28. Yamamoto Y, Watanabe Y, Ishida N, Hidaka T, Sugishita H, Yoshida M, Yukumi S, Sato K, Nakagawa H, Horiuchi A and Kawachi K: Collagen gel droplet-embedded culture drug sensitivity test in human breast cancer. *Gan To Kagaku Ryoho* 35: 793-796, 2008.
29. Nakagawa T, Takahashi H, Kamiyama T, Nakanishi K, Takahashi M, Watanabe K, Taguchi K, Tsukahara M, Nakajima H, Kamachi H, *et al*: In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures. *Gan To Kagaku Ryoho* 31: 2145-2149, 2004 (In Japanese).
30. Suzuki M, Ishikawa H, Tanaka A and Mataga I: Heterogeneity of anticancer drug sensitivity in squamous cell carcinoma of the tongue. *Hum Cell* 24: 21-29, 2011.